Abstract: Adenosine is a neuromodulator with several functions in the central nervous system (CNS), such as inhibition of neuronal activity in many signaling pathways. Most of the sedating, anxiolytic, seizure-inhibiting and protective actions of adenosine are mediated by adenosine A1 receptors (A1R) on the surface of neurons and glia. Positron Emission Tomography (PET) is a powerful in vivo imaging tool which can be applied to investigate the physiologic and pathologic roles of A1R in the human brain, and to elucidate the mechanism of action of therapeutic drugs targeting adenosine receptors, nucleoside transporters and adenosine-degrading enzymes. In this review article, we discuss (i) functions of adenosine and its receptors in cerebral metabolism; (ii) radioligands for A1R imaging: xanthine antagonists, non-xanthine antagonists, and agonists; (iii) roles of A1R in health and disease, viz. sleep-wake regulation, modulation of memory retention and retrieval, mediating the effects of alcohol consumption, protecting neurons during ischemia and reperfusion, suppression of seizures, modulating neuroinflammation and limiting brain damage in neurodegenerative disorders. The application of PET imaging could lead to novel insights in these areas. Finally (iv), we discuss the application of PET in pharmacodynamic studies and we examine therapeutic applications of adenosine kinase inhibitors, e.g. in the treatment of pain, inflammation, and epilepsy.
INTRODUCTION

Sources, Regulation and Fate of Extracellular Adenosine
The purine nucleoside adenosine is not a classical signaling substance, as adenosine is neither stored nor released from vesicles. The nucleoside plays a neuromodulatory role by affecting the excitability of neurons that release neurotransmitters such as glutamate, -amino butyric acid (GABA), acetylcholine and dopamine [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . Adenosine is involved in homeostatic reduction of cellular excitability during stress and trauma via its interaction with receptors on the cell surface. Moreover, adenosine is involved in the regulation of synaptic plasticity. Balanced activation of inhibitory and facilitatory adenosine receptors modulates long term potentiation (e.g., in the hippocampus) [13] [14] [15] .
Metabolic pathways involved in the formation and removal of adenosine are presented in Fig. (1) . Extracellular adenosine may originate from intracellular adenosine -which can pass the plasma membrane via an equilibrative nucleoside transporter (ENT), or by hydrolysis of locally released adenine nucleotides such as adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP) and to a lesser extent cyclic adenosine monophosphate (cAMP). Production of extracellular adenosine is the result of the breakdown of such nucleotides by ecto-nucleotidases [16] [17] [18] . The rate-limiting step is the conversion of AMP to adenosine which is catalyzed by ecto-5'-nucleotidase (CD73). The biochemical and pharmacological properties of this enzyme have been extensively characterized [16, 19] . 5'-Nucleotidase is inhibited by ATP and ADP [18] . The quantititative importance of this mechanism has been confirmed by a kinetic characterization of the breakdown of extracellular ATP at the cholinergic striatal synapse [20] .
Extracellular adenosine is subject to metabolic degradation by adenosine deaminase (ADA) which results in the formation of inosine [21] . Another route of adenosine inactivation is the reversible reaction catalyzed by S-adenosyl homocysteine (SAH) hydrolase [22] . Formation of SAH from adenosine and *Address correspondence to this author at the Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713GZ Groningen, The Netherlands; Tel: +31-50-3613215; Fax: +31-50-3611687; E-mail: a.van.waarde@umcg.nl homocysteine is restricted since homocysteine levels are ratelimiting. In the brain, the SAH pathway is a quantitatively negligible pathway of adenosine catabolism [23] . The major route of adenosine removal under normal conditions is phosphorylation to AMP by adenosine kinase (AK).
Classification of Adenosine Receptors
The adenosine receptor (AR) family consists of the A 1 , A 2A , A 2B and A 3 subtypes (A 1 R. A 2A R, A 2B R and A 3 R, respectively). A 1 R and A 3 R inhibit whereas A 2A R and A 2B R stimulate production of the second messenger, cAMP. A 1 R and A 2A R are activated by nanomolar concentrations of adenosine whereas A 2B R and A 3 R become activated only when adenosine levels rise into the micromolar range during inflammation, hypoxia or ischemia [24] [25] [26] . The four AR subtypes from rat, mouse, human and other species have been pharmacologically recognized, cloned, purified and expressed [27] [28] [29] . In the following pages, we will focus on the A 1 R and the potential contribution of positron emission tomography (PET) imaging to the study of its involvement in physiological processes.
Regional Distribution and Signaling of A 1 R
The A 1 R is the most strongly preserved AR subtype among different animal species [28] . A 1 Rs exhibit the highest affinities for adenosine and synthetic agonists of all AR subtypes [30] . They are distributed throughout the body and are also highly expressed in the brain, especially in hippocampus, frontal cortex, thalamic nuclei, basal ganglia and dorsal horn of the spinal cord. Peripheral organs with high A 1 R expression include eye, adrenal gland, heart and aorta.
The regional distributions of A 1 R in human and rodent brains are similar but not completely identical. In human cerebellum, A 1 R densities are low in contrast to rat cerebellum, where moderate A 1 R expression is noted [31] [32] [33] [34] [35] [36] . Different neurons express different levels of A 1 R. In rat brain, the highest A 1 R immunoreactivity is observed in pyramidal neurons of layer 5 of the cerebral cortex, and in pyramidal cells in fields CA2 and CA3 of the hippocampus. In layer 5, immunoreactivity is detected in cell bodies, dendrites and initial segments of axons [37] .
Activation of A 1 Rs inhibits adenylyl cyclase, closes voltagedependent Ca 2+ channels, and activates K + channels. Signalling of this AR subtype occurs through G i/o pathways in various cells (including neurons). As a result, the neuronal activity is suppressed [38, 39] . In presynaptic regions, adenosine inhibits neurotransmitter and neuropeptide release, including the release of glutamate, substance P and calcitonin gene related peptide [40] . In postsynaptic areas, adenosine abolishes sensory transmission and causes membrane hyperpolarisation [41, 42] .
RADIOLIGANDS FOR A 1 R IMAGING
PET is a medical imaging technique providing information on tissue biochemistry rather than anatomy. PET imaging has several unique properties: high sensitivity, low radiation dose, possibility to correct data for attenuation and scatter (thus quantitative), radioactive labeling of natural substances or drugs with high specific radioactivity so that these can be used as tracers to monitor the pharmacokinetics of the non-radioactive compounds. PET may therefore be applied to measure regional AR densities in the living human brain and the dose-dependent occupancy of cerebral AR by therapeutic drugs. A comprehensive overview of PET tracers for the different AR subtypes has been presented in some recent reviews [43, 44] .
Several ligands for PET imaging of A 1 R have been prepared (see Table 1 and Fig. 2) . These include xanthine A 1 R antagonists, non-xanthine A 1 R antagonists and A 1 R agonists. All compounds bind with nanomolar affinity to A 1 R. 
PHYSIOLOGICAL ROLE OF A 1 R AND CHANGES OF A 1 R EXPRESSION IN DISORDERS OF THE CNS
Sleep-Wake Regulation
Adenosine plays an important role in the induction of sleep after prolonged wakefulness [47] . Prolonged wakefulness with its associated prolonged neuronal activity increases extracellular adenosine levels in the forebrain of conscious cats, whereas these levels diminish during sleep [48] . A [
18 F]CPFPX-PET study in humans has indicated that in addition to changes of extracellular adenosine, A 1 R are upregulated in cortical and subcortical regions of the brain after prolonged wakefulness (max. 15.3%), which suggests that changes of A 1 R expression are contributing to homeostatic sleep regulation [49] . Short periods of total sleep deprivation (3 or 6 h) result in increases of A 1 R mRNA but no 
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Non-xanthines Fig. 3 ) saturation binding assays have indicated that A 1 R densities in cortical and subcortical regions of rat brain are increased not only after total sleep deprivation, but also after 48 and 96 h of partial, rapid eye movement (REM) sleep deprivation, whereas affinity (K d ) values for agonist binding are not significantly altered [53] . After restriction of sleep and also after performance of a difficult learning task, cerebral synchronized slow wave activity (SWA) is enhanced during the next sleeping period, and this activity is related to the subsequent improvement of cognitive performance [54, 55] . Activation of A 1 R is necessary for the increase of SWA. If this increase is impaired (e.g. because of knockout of the A 1 R gene) animals fail to maintain normal cognitive function. Thus, adenosine appears to be an important homeostatic sleep factor, and A 1 Rs are involved in the regulation of sleep.
After administration of a selective A 1 R agonist, N6-Cyclopentyladenosine (CPA, Fig. 3) , either by the systemic or the cerebroventricular route, SWA increased in rats during non-REM sleep [56] . Such stimulation of A 1 R mimics the effect of total sleep deprivation in rodents. A similar effect on sleep is observed when extracellular adenosine levels in the mammalian brain are raised by administering inhibitors of nucleoside transport [57] . When levels of extracellular adenosine in the basal forebrain are raised by microdialysis, vigilance of rats is significantly impaired [58] . This effect on vigilance is completely blocked after co-administration of a selective A 1 R antagonist, 8-cyclopentyltheophylline (CPT, Fig.  3 ), with adenosine [58] . On the other hand, infusion of CPT into the basal forebrain diminishes the sleeping ability (both slow-wave and REM sleep) of cats [57] . Infusion of A 1 R antisense in the cholinergic basal forebrain of rats inhibits the translation of A 1 R mRNA, resulting in decreased non-REM sleep and increased wakefulness [59] . Such pharmacological experiments have provided additional support for the important role of A 1 R in sleep regulation. Agonists for this receptor usually promote [60] [61] [62] while antagonists diminish [60, 63] sleep.
In rat brain, prolonged wakefulness with accompanying increases of extracellular adenosine and stimulation of A 1 R increases the activity of the transcription factor NF-kappaB [64, 65] . This transcription factor regulates expression of several modulatory substances, such as interleukin-1-ß and tumor necrosis factor , which shows a diurnal rhythm. Some effects of adenosine on sleep homeostasis, particularly the phenomenon of "sleep debt" may be triggered via this mechanism.
Orexinergic neurons in the lateral hypothalamus also express A 1 R [66] . Adenosine and A 1 R agonists inhibit activity of the hypocretin/orexin neurons in this area via A 1 R which promotes sleep [67, 68] . On the other hand, blockade of A 1 R in such neurons causes a pronounced increase in wakefulness [68, 69] . Adenosine reduces the frequency of action potentials in hypocretin/orexin neurons by depressing excitatory synaptic transmission to these cells. An additional mechanism involved in the sleep-promoting effects of adenosine may be suppression of the activity of histaminergic neurons in the tuberomammillary nucleus via A 1 R [70] . Thus, in addition to its effects in basal forebrain, adenosine promotes sleep by reducing the activity of orexinergic and histaminergic neurons in the hypothalamus [67] .
An additional brain region involved in sleep regulation is the pontine reticular formation. Microinjection of the A 1 R agonist N6-cyclopentyladenosine (CPA) or inhibition of the formation of cAMP in this area increases REM sleep [71] . Another study has shown that administration of an A 1 R agonist (N6-psulfophenyladenosine) decreases the (arousal-promoting) release of the neurotransmitter acetylcholine and increases the recovery time from halothane anesthesia [7] .
Neurons in the previously mentioned brain areas are wakeactive. Thus, suppression of their activity via stimulation of A 1 R promotes sleep. In contrast to the regions mentioned above, the lateral preoptic area of rat hypothalamus is an area with an abundance of sleep-active neurons. A 1 R agonists and the adenosine transport inhibitor 4-nitrobenzyl-thioinosine have opposite effects in this area as in other regions of the brain, i.e. they increase wakefulness rather than sleep [72] . Thus, the adenosine-mediated effects on the sleep-wake cycle are both neuron-and regiondependent.
PET may be applied to study the involvement of A 1 R in the regulation of human sleep. Increased expression of A 1 R in the human cortex after prolonged wakefulness has already been demonstrated [49] . Future PET studies could examine the effect of partial (REM) sleep deprivation in humans, and cerebral A 1 R expression in sleeping disorders like narcolepsy.
Learning and Memory
Acute stimulation of A 1 R by agonists at micromolar doses has been reported to severely impair both the acquisition and retention of memory in various animal and in vitro models, such as long-term potentiation in rat hippocampal slices [73] , passive avoidance retention in mice [74, 75] , working memory in a three-panel test [76] , and acquisition of conditional fear conditioning [77] or shortterm social memory in rats [78] . These cognitive deficits are attenuated, or abolished, when brain slices or experimental animals are pretreated with selective A 1 R antagonists such as DPCPX. Thus, activation of A 1 R in many regions of the CNS (hippocampus, ventral striatum, posterior cingulate cortex) may negatively modulate information processing in the brain and may impair memory retention [73] [74] [75] [76] . Depending on the test setup (dose, region of administration, time of the day), acute administration of a selective A 1 R antagonist has either no effect or it can facilitate memory performance of rodents [75, 78, 79] .
In contrast to acute administration, chronic administration of an A 1 R agonist (daily i.p. injections of CPA during a 9-day period) results in facilitation of spatial learning and memory of mice tested in a Morris water maze. These improvements are probably related to downregulation of A 1 R [80] .
However, studies of the behavioral phenotype of mice lacking A 1 R have indicated that A 1 R are not essential for rodent learning. Such mice show normal motor coordination but reduced muscle strength. Overall spontaneous motor activity is similar to that of wild-type controls, but activity peaks during the light/dark cycle are flattened, which is consistent with A 1 R regulating the sleep-wake rhythm. A 1 R -/-mice show enhanced aggression and decreased exploratory behavior indicating increased anxiety. However, their working memory in five different water maze tasks is not significantly impaired. The knockouts have a shorter lifespan than controls (LT 50 reduced from 26 to 20 months), which suggests that A 1 R play an important protective role in mammalian tissues during aging [81, 82] . In a follow-up study which included a six-arm radial tunnel maze test, A 1 R -/-mice were found to display normal spatial learning but to habituate more slowly to the test environment [83] . Thus, stimulation of A 1 R may be required for habituation, i.e. suppression of the processing of irrelevant information.
Effects of Ethanol
Various effects of alcohol consumption appear to be mediated by adenosine and A 1 R. Ethanol metabolism in the liver causes formation of acetate, which circulates in the body at millimolar concentrations and is finally incorporated into acetyl-coenzyme A with concomitant production of AMP and adenosine [84] . Acute administration of ethanol results also in inhibition of the facilitated diffusion of nucleosides [84, 85] . The inhibitory effect is specific for one particular subtype of ENT (ENT1) [86, 87] and can be observed both in cultured cells [84, 85, 88] and in cerebellar synaptosomes [89, 90] . Thus, ethanol augments the rate of adenosine formation and reduces adenosine uptake. Both mechanisms may increase the extracellular levels of adenosine.
Initial attempts at measuring changes of adenosine levels within the brain after administration of ethanol or acetate were unsuccessful, probably because it is difficult to homogenize tissue, or to collect adenosine, while avoiding adenosine degradation [91, 92] . Later analytical and microdialysis studies indicated that the levels of acetate and extracellular adenosine in cortical areas of rat brain are significantly increased (up to 4-fold) after administration of physiologically relevant doses of ethanol [93, 94] .
A functional relationship between ethanol and adenosine was suggested by the fact that dipyridamole, an inhibitor of ENT1, promotes ethanol-induced motor impairment (EIMI) [95] . Increases of EIMI were also noted after administration of the ENT inhibitor dilazep or the AR agonist R-PIA, whereas the AR antagonist theophylline suppressed EIMI [96] Several subsequent studies demonstrated that A 1 R agonists accentuate and A 1 R antagonists attenuate EIMI, when infused into the motor cortex [97] or striatum [98, 99] . AR antagonists like theophylline or caffeine (Fig. 3) , and lipophilic AR agonists like cyclohexyladenosine (CHA) modulate EIMI also after systemic administration. Experiments in which subtype-selective AR antagonists were administered either alone or in combination with agonists have indicated that the A 1 R subtype is involved in modulation of EIMI, although a contribution of A 2 R cannot be ruled out [97, 99, 100] . Co-administration of cAMP analogs, pertussis toxin or the (R)-and (S)-enantiomers of AR agonists with ethanol suggested involvement of G-protein-coupled A 1 R and adenylate cyclase [101, 102] . The importance of A 1 R was proven by the fact that A 1 R antisense, applied orally, systemically or directly into the striatum or cerebellum reduced the regional A 1 R density and antagonized EIMI, whereas a mismatch control sequence had no effect [103, 104] . A 1 R in the motor cortex, striatum and cerebellum, but not in hippocampus [98] appear to affect EIMI via adenosine-induced decreases in glutamate release [105, 106] and/or changes of chloride conductance via chloride channels coupled to the GABA-benzodiazepine receptor complex [102, 107] .
Besides playing a role in EIMI, adenosine is involved in other physiological responses related to the consumption of ethanol. The ENT1 inhibitor dipyridamole prolongs, and the AR antagonist theophylline reduces the duration of ethanol-induced sleep [95] . Ethanol and acetate also potentiate the anesthetic effect of sevoflurane and isoflurane through metabolically generated adenosine and stimulation of A 1 R [108] [109] [110] [111] . In humans, the AR antagonist caffeine reverses most of the sedating effects of ethanol (sleepiness, lack of alertness, impaired memory) but not ethanolinduced dizziness [112] . A recent study in rodents showed that ethanol promotes non-REM sleep but does not affect REM sleep. The somnogenic effect of ethanol is related to adenosine inhibition of wake-promoting neurons in the basal forebrain via A 1 R. Bilateral microinjections of the selective A 1 R antagonist DPCPX in this area reduce the effect of ethanol on non-REM sleep [113] . A study in which ethanol was administered to mice, either alone or in combination with selective AR agonists and antagonists, and animals were tested for anxiety in the elevated plus-maze, has indicated that activation of A 1 R also mediates the anxiolytic effect of ethanol [114] .
Adenosine and A 1 R are not only involved in the motor impairing, sleep-promoting and sedating effects of ethanol, but also in counteracting the negative symptoms of ethanol withdrawal. Withdrawal signs in rats such as tremors and audiogenically induced seizures are suppressed by an A 1 R agonist (CCPA), and this beneficial effect is blocked after co-administration of an A 1 R antagonist (DPCPX) [115] . Other negative symptoms of ethanol withdrawal, such as hyperexcitability [116] and increased anxiety [117, 118] are also ameliorated upon stimulation of A 1 R. AR antagonists (DPCPX, caffeine) are neurotoxic when administered during ethanol withdrawal, particularly in female mice, and these neurotoxic effects are reversed by an A 1 R agonist (CCPA). Sex differences observed for neurotoxicity of A1R antagonists during ethanol withdrawal are probably related to N-methyl-D-aspartic acid (NMDA)-receptor-mediated downstream signaling which is more pronounced in females than in males [119, 120] .
Observed changes of A 1 R densities in rodent brain during ethanol exposure appear to be dependent on the experimental paradigm, the radioligand which is used for binding assays and the brain area that is studied. Using the agonist [ 3 H]R-PIA, increases of B max without any change of K d were noted in the cerebral cortex of rats, 15 min after administration of ethanol (1.5 g/kg, [96] ). In a later study, the same authors noted that the observed increase (+ 40.7%) is transient, receptor densities returning to the control value within 60 minutes [121] . Chronic administration of ethanol is also accompanied by an increased binding (+23%) of the agonist 2-chloro-N6-cyclopentyladenosine ([ 3 H]CCPA, Fig. 3 ) in rat cerebral cortex. This increase persists longer than the one observed after acute administration. Elevated receptor densities are observed 3, 12 and 24 h after the last consumption of ethanol, but the ethanol effect disappears after 3 to 6 days [122] . Increased binding of the A 1 R agonist [
3 H]CHA was also noted in the cerebral cortex of mice following chronic administration of ethanol [123] . The increase is most pronounced after multiple episodes of ethanol withdrawal, and may be a compensatory inhibitory response to withdrawal seizures [124] . In contrast to the changes observed with A 1 R agonists, cortical binding of the A 1 R antagonist [
3 H]DPCPX is not affected by ethanol treatment [116, 122] . Whereas most studies reported a transient increase of A 1 R agonist binding upon acute or chronic administration of ethanol, one old [95] and one recent [125] study reported decreases of A 1 R expression in some brain areas of rats. Decreased A 1 R expression in the wake-promoting basal forebrain may be related to insomnia associated with ethanol withdrawal [125] .
Only a single PET study has examined changes of A 1 R expression after acute exposure of animals to ethanol [126] . In that study, Wistar rats were treated with a combination of ethanol and the AK inhibitor ABT-702, and scanned with the A 1 R ligand [ 11 C]MPDX. A striking (40-45%) increase of tracer distribution volume and binding potential was noted in target areas such as hippocampus, striatum and cerebral cortex, 20-90 min after treatment. Additional PET studies could be performed to study the effect of ethanol only, either in rodents or in the human brain.
Cerebral Ischemia
Levels of extracellular adenosine in the brain are dramatically increased during ischemia. In patients with transient ischemic attack (TIA) or stroke, a rapid rise of the plasma concentration of adenosine occurs in peripheral venous blood, presumably because of spillover from the brain, and this increase persists for days (TIA) or weeks (stroke) [127] . Extracellular adenosine in the brain inhibits synaptic neurotransmission including the release of excitatory amino acids [128, 129] , leading to a better matching of energy demand and energy supply in ischemic areas and a reduction of delayed excitotoxicity [130] . Through A 1 R, adenosine promotes both the spontaneous electrical shutdown of the ischemic brain [131] and post-ischemic electrocortical burst suppression [132, 133] . When levels of extracellular adenosine in mouse brain are reduced by transgenic overexpression of AK, postischemic cell death is increased [134] .
The importance of A 1 R stimulation was also evident in studies regarding ischemic preconditioning. When neurons or living animals are exposed to a short period of sublethal ischemia, they are better protected to a subsequent serious ischemic insult. This beneficial effect of preconditioning disappears in the presence of an A 1 R antagonist like DPCPX, suggesting that A 1 R stimulation is involved [135] [136] [137] [138] [139] . The mechanisms underlying induction of rapid tolerance by a sublethal ischemic insult are not fully understood. Increases in protein kinase C activity, mitogen-activated protein (MAP) kinase activity, Akt activity, nitric oxide production and mitochondrial K ATP channels may all be involved [135] [136] [137] [138] [139] . Activation of presynaptic K + channels via stimulation of A 1 R may decrease evoked neurotransmitter release by hyperpolarization of the presynaptic membrane and thus improve resistance of the brain to ischemia.
In various animal and in vitro models, acute administration of A 1 R agonists [140] [141] [142] [143] , inhibitors of adenosine uptake (propentofylline but not dipyridamole) [144] , or inhibitors of AK [134] has been shown to result in protection against ischemic brain damage and reperfusion injury. Long-term treatment of gerbils with caffeine causes an upregulation of cerebral A 1 R (10-17%) and greater resistance of neurons to ischemia induced by bilateral carotid artery occlusion [145] . Increasing the binding of adenosine to A 1 R by administration of an allosteric enhancer also results in decreased brain damage after a hypoxic insult [146] . In contrast, acute administration of an A 1 R antagonist such as DPCPX aggravates the consequences of cerebral ischemia [141, 142, 147] .
Therapeutic application of A 1 R agonists in stroke patients may be complicated by the fact that such compounds can have diametrically opposite effects after chronic and acute administration. Acute treatment with an A 1 R agonist may reduce postischemic neuronal losses whereas chronic treatment with the same compound increases brain damage [142, 148] . Other agonists are neuroprotective even during chronic treatment [149] . The underlying mechanisms are far from clear since the consequences of chronic administration of A 1 R ligands can not always be related to up-or downregulation of A 1 R [142] .
Many studies have examined changes of A 1 R expression in the brain of experimental animals after cerebral ischemia. In most studies, rapid decreases of A 1 R mRNA and protein were observed during reperfusion [150] [151] [152] but in one study, decreases were noted at the mRNA but not the protein level [153] . These (slightly) discrepant findings may be due to the fact that different models of ischemia were employed and animals were examined at different intervals after the ischemic insult. Some changes appear only at intervals greater than 24 hours. Changes of A 1 R expression during ischemia have been little examined, as opposed to changes during reperfusion. In a single study, increases of A 1 R expression (at the mRNA and protein level) were noted during bilateral carotid artery ligation with a return to normal values immediately after reperfusion [154] .
An interesting study from Japan examined changes of cerebral A 1 R in cat brain following an ischemic insult, using PET and the radioligand 11 C-MPDX. Decreases of A 1 R were noted, and the magnitude of these losses increased with increasing severity of the insult. The extent of 11 C-MPDX binding directly after reperfusion appeared to be a sensitive predictor of survival and disease symptoms during the follow-up period which lasted up to 2 months [155, 156] .
Epilepsy
Adenosine inhibits the release of excitatory neurotransmitters and suppresses cellular activity and energy demand. Based on this evidence, it has been proposed that adenosine is a powerful endogenous anticonvulsant substance [157] . In amygdala-kindled rats, intracerebrally administered A 1 R agonists, such as 2-chloroadenosine (Fig. 3) and PIA, could indeed suppress seizures [158] [159] [160] [161] [162] . These substances were also effective in other animal models of eplilepsy, such as entorhinal cortex kindling [163] , piriform cortex kindling [164] , hippocampal kindling [162, 165] , caudate nucleus kindling [162] , intrahippocampal injection of kainic acid [166] , intraperitoneal injection of pilocarpine [167] and hypoxia-induced convulsions [168] . The location of intracerebral administration is probably important for the therapeutic outcome [169] . In many studies, co-administration of A 1 R antagonists was shown to result in a reduction of the anticonvulsant effect, which indicates that the A 1 R subtype is involved in the beneficial action of the agonists.
Inhibitors of the enzyme AK can be systemically administered and can increase extracellular adenosine levels in metabolically active brain regions. Such compounds show similar anticonvulsant actions as A 1 R agonists but lack the undesired peripheral side effects of these drugs [170] . AK is regionally overexpressed in epilepsy and this overexpression appears to contribute to the development and progression of seizure activity [134, 171, 172] . Local administration of adenosine by implanting encapsulated myoblasts could be a promising strategy for long term treatment of focal epilepsy [173] Further evidence for the involvement of the A 1 R in seizure suppression was obtained in animal models where A 1 R antagonists were administered. In a cat model of epilepsy (general seizures induced by intracortical injection of penicillin), the A 1 R antagonist CPT significantly prolonged the cycle period of seizures by increasing the duration of ictal discharge, in contrast to 7-aminobutyric acid or opioid peptides [174] . Adenosine may accumulate during the ictal phase and be cleared during the interictal phase in status epilepticus. In a rat model of epilepsy (electrically induced seizures), secondary seizures were prolonged after administration of an A 1 R antagonist, and partial seizures were converted into generalized motor seizures [175] . In another rat model of epilepsy (i.p. administration of pilocarpine), the A 1 R antagonists DPCPX and 3,7-dimethyl-1-propargylxanthine (DPMX) showed proconvulsant effects, by significantly reducing the latency to develop status epilepticus [167] . Theophylline also lowered the seizure threshold and prolonged hyperthermia-induced seizures in juvenile rats [176] . Using a selective A 1 R antagonist (CPT), evidence was obtained that the inhibitory effect of low frequency stimulation of the perforant path on kindling acquisition in rats is mediated by stimulation of A 1 R [177] .
Changes of cerebral A 1 R densities have been assessed both in animal models of epilepsy and in human brain post mortem. In a rat model of acute general seizure (i.p. injection of a convulsive dose of bicuculline), a widespread increase of A 1 R ( 3 H-CHA binding) was noted, which was particularly evident in hippocampus, amygdala, substantia nigra and septum [178] . In a mouse model of general seizure (pentylentetrazol-induced convulsion) [179] , A 1 R were upregulated in most brain areas but downregulated in the basal ganglia [180] . In tissue samples acquired from patients with temporal lobe epilepsy, a 48% increase of A 1 R density was observed in neocortex as compared to control samples from nonepileptic subjects [181] .
However, in another study on human temporal lobe epilepsy, A 1 R binding in temporal cortex was found to be reduced compared to normal postmortem controls [182] . A 15% decline of A 1 R density was also noted in the basal ganglia and thalamic nuclei of genetic absence epilepsy rats from Strasbourg compared to wildtype littermates [183] . Even greater losses of A 1 R were noted in the hippocampus and cerebral cortex of kainate-treated, hippocampuskindled and amygdala-kindled rats, animal models of chronic epilepsy [184] [185] [186] [187] .
These conflicting results (either an upregulation or downregulation of A 1 R) may be related to differences in the experimental setup in animal models and differences in patient selection in human studies. An acute seizure, or a limited number of seizures may be accompanied by upregulation of A 1 R, or increased coupling of A 1 R to G-proteins [188, 189] , as a protective mechanism enhancing the anticonvulsant effect of endogenous adenosine. However, chronic seizures may cause a significant death of neurons with accompanying losses of A 1 R. The effects of partial and general seizures may also be different and the age (or developmental stage) of the subjects may affect the response of A 1 R to kindling [178, 190] .
Traumatic Brain Injury
Studies in A 1 R knockout mice have confirmed that this subtype plays an important role in suppressing neuronal hyperactivity. When normal and A 1 R knockout mice were subjected to controlled cortical impact -an animal model of traumatic brain injury (TBI) -seizure scores were much higher in the knockouts and only the knockout animals developed lethal status epilepticus [191] . Similarly, unilateral hippocampal kainate injection caused nonconvulsive status epilepticus in wild-type mice but severe convulsions and subsequent death of the animals in A 1 R knockouts [192] . The authors concluded that activation of A 1 R by adenosine is crucial in keeping an epileptic focus localized. Status epilepticus results in widespread adenosine release throughout the brain and suppression of the excitability of neurons remote from the epileptic focus via stimulation of A 1 R. In A 1 R knockout mice, this protective mechanism is lacking, so that severe convulsions and lethal status epilepticus can develop [192] .
In another animal study on mild TBI, A 1 R knockout mice were shown to display a 20-50% enhanced microglial response compared to their wild-type littermates. Moreover, stimulation of A 1 R in BV-2 (immortalized mouse microglia) cells inhibited microglial proliferation [193] . Thus, A 1 Rs appear to play an anti-inflammatory role in TBI-induced neuroinflammation.
To the best of our knowledge, no PET studies on changes of A 1 R expression in epileptic patients or in animal models of epilepsy and TBI have been performed. Thus, there is considerable opportunity for imaging studies in this area.
Neuroinflammation
Besides its well-known function as an inhibitor of neuronal overactivity and its involvement in the regulation of sleep, adenosine has been proposed to act as an endogenous antiinflammatory agent [194] . In the CNS, A 1 Rs are expressed not only on neurons but also on glia [195] . A 1 R stimulation in microglia, the endogenous immune cells of the brain, may have both pro-and anti-inflammatory effects, depending on the presence or absence of other factors in the environment, such as phorbol 12-myristate 13-acetate [196] . An early study reported that simultaneous activation of both A 1 R and A 2A R stimulates microglial proliferation, whereas selective A 1 R or A 2A R agonists when applied alone have no effect [195] . However, later studies have indicated that in most situations, A 1 R agonists suppress neuroinflammation.
In cultured astrocytes, CCPA enhanced the release of nerve growth factor [197] , a compound which is essential for neuronal protection and a suppressor of neuroinflammation within the specific environment of the brain [198] . In plasmacytoid dendritic cells, adenosine has been suggested to play a dual role: first, chemotaxis to the site of inflammation is stimulated via A 1 R, then, the extent of the inflammatory response is limited by inhibition of the production of several cytokines such as interleukin-6, interleukin-12 and interferon- [199] .
The importance of A 1 R in controlling neuroinflammation was highlighted by studies of experimental allergic encephalomyelitis (EAE). Mice lacking A 1 R developed a much more severe, progressive-relapsing form of EAE than their wild-type littermates. Reduced densities of A 1 R in microglia of wild-type mice were observed during the neuro-inflammatory phase of EAE. Upregulation of A 1 R by treatment of normal mice with caffeine reduces EAE severity, and this beneficial effect of caffeine can be enhanced by concomitant administration of an A 1 R agonist [200] . In a rat model of neuroinflammation (EAE induced by guinea pig spinal cord homogenates), chronic caffeine treatment results in upregulation of A 1 R and attenuation of EAE pathology [201] . Experimentally induced neuroinflammation by chronic infusion of lipopolysaccharide (LPS) into the fourth ventricle of young rats, and natural microglia activation in aged rats are also attenuated after treatment of animals with caffeine [202] . In contrast to EAE (an animal model of chronic neuro-inflammation which is associated with a downregulation of A 1 R), acute inflammation of mouse brain after administration of LPS leads to increased A 1 R expression in cortical areas and this response is dependent on the transcription factor NF-kappaB [203] .
An interesting study examined the role of A 1 R in brain tumors. Gliomas do not consist only of tumor cells but to a large extent (up to 30%) also of microglia and macrophages. Microglial cells accumulate particularly at the tumor rim. In the tumor environment, microglia acquires a different phenotype which is associated with expression of matrix metalloprotease II (MMP2). After acquisition of this novel phenotype, the microglial cells do not suppress but can actually promote tumor growth and invasion since these processes are MMP2-dependent. Experimental glioblastomas grew more vigorously and were associated with larger numbers of microglial cells in A 1 R knockout mice than in wild-type mice. In wild-type animals, A 1 R were up-regulated in microglia in contact with tumor cells but not in the rest of the brain. When glioma and microglia cells were cultured together in vitro, A 1 R agonists suppressed the growth of tumor cells, but in the absence of microglia, the same compounds stimulated tumor growth. Thus, adenosine attenuates glioblastoma growth, acting through microglial A 1 R [204] .
Changes in cerebral A 1 R density caused by glioma invasion have been examined with the tracer [
18 F]CPFPX and PET, both in an animal model (F98 glioma-bearing rats) and in a patient with recurrent glioblastoma multiforme. In the animal model, A 1 R were also quantified by in vitro and in vivo autoradiography and immunohistochemical analysis. A 1 R were shown to be upregulated (by 36 to 46%) in a zone directly surrounding the tumor, and to be localized in activated astrocytes [205] . It would be interesting to study changes of A 1 R expression with microPET in animal models of neuroinflammation (e.g., the EAE model, the LPS model, or virally induced encephalitis). Such studies have not yet been reported.
Human Diseases of the CNS
Alzheimer's Disease (AD)
Since A 1 R signaling can be neuroprotective, many investigators examined changes of regional A 1 R density in human brain in neurodegenerative disorders. Initial autoradiographic studies were focused on AD and the hippocampus, a brain region involved in memory. A significant loss of A 1 R was observed in the CA1 (-47%) and dentate gyrus molecular layers (-46%) of the hippocampus but not in the CA3 [206] . Another study reported 40-60% decreases in all areas of the hippocampus, the most striking losses occurring in the molecular layer of the dentate gyrus [207] . Still another investigation reported substantial decreases in the dentate gyrus but A 1 R densities close to normal in CA1 and CA3 [208] ]CPDPX) in the AD hippocampus were later directly compared. Both ligands detected prominent losses of A 1 R in the dentate gyrus. Decreased agonist binding was observed in CA1 and outer layers of the parahippocampal gyrus, whereas losses of antagonist binding were noted in the subiculum and CA3. These decreases reflected reductions of receptor number (B max ) rather than reductions of the affinity (K D ) of A 1 R for the radioligands [209] In the striatum of AD patients, 30-36% losses of A 1 R were noted both in the caudate nucleus and putamen, and these losses appeared to parallel the decrease of choline acetyl transferase [210] .
An immunohistochemical study from Spain showed that A 1 R are redistributed in the hippocampus and cerebral cortex of AD patients in comparison to age-matched controls. A 1 R accumulate in degenerating neurons and are co-localized with ß-amyloid in senile plaques and with tau in neurons with tau deposition. Studies in the human neuroblastoma cell line SH-SY5Y indicated that A 1 R stimulation increases the production of soluble forms of amyloid precursor protein, and the phosphorylation and translocation of tau to the cytoskeleton. By inhibiting the deposition of amyloid and enhancing the translocation of tau, A 1 R stimulation may slow down the process of neurodegeneration [211] .
An upregulation of A 1 R was detected in the frontal cortex of AD patients (both at early and advanced stages of the disease), using quantitative autoradiography and the radioligand [ 3 H]DPCPX [212] . However, a PET study in AD patients and elderly normal subjects indicated significant decreases of the binding potential of [ 11 C]MPDX in the temporal and medial temporal cortices and thalamus of the patients with no significant change in other areas of the brain [213] (Fig. 4) . Discrepant findings in human studies may be related to the facts that different patient groups were selected (early vs. late onset AD), different brain regions were examined, and different techniques were used for quantification (immunohistochemistry, ligand binding). Moreover, a transient upregulation of A 1 R may be followed by an eventual receptor loss.
Pick's and Creutzfeld-Jakob Disease
In the frontal cortex of individuals with Pick's [214] and Creutzfeldt-Jakob [215] 
Multiple Sclerosis (MS)
Several studies have reported changes of AR signaling in patients with MS. Plasma levels of TNF-in such patients are significantly higher and levels of adenosine are significantly lower than in control subjects. Stimulation of peripheral blood mononuclear cells (PBMC) with a selective A 1 R agonist (R-PIA) inhibits the mitogen-stimulated production of TNF-in healthy subjects but not in MS patients, whereas the opposite is observed for the mitogen-stimulated production of interleukin-6 [216] . A 1 R densities in PBMC and in brain tissue from MS-patients are significantly decreased (by 53% and 49%, respectively) compared to age-matched controls [217] . Thus, both A 1 R densities and the coupling of A 1 R to cytokine signaling systems appear to be altered in MS. However, no PET studies with A 1 R ligands have been performed in this patient group.
Parkinson's Disease
In the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease, the drug paeoniflorin proved capable of reducing neurodegeneration and inhibiting neuroinflammation by activation of A 1 R [218] . Thus, modulation of neuroinflammation via A 1 R may be a novel approach towards treatment of neurodegenerative disease. Deep brain stimulation (DBS) is frequently applied for the treatment of movement disorders and may also benefit individuals with psychiatric disease. Recently, it was shown that the mechanism underlying the beneficial effect of DBS is a local release of ATP which is extracellularly metabolized to adenosine and suppresses tremor via A 1 R. The effect of DBS can be mimicked by intrathalamic infusion of A 1 R agonists. On the other hand, AR antagonists like caffeine can trigger or exacerbate essential tremor [219] .
Schizophrenia
A partial loss of A 1 R during birth and a corresponding reduction of the control of dopamine activity in later life has been proposed to play a role in the inhibitory deficit in schizophrenia [220, 221] . Association between a single nucleotide polymorphism of the A 1 R gene (rs3766553) and schizophrenia was indeed noted in a Japanese population [222] . PET studies of cerebral A 1 R in patients with schizophrenia have not yet been performed.
PHARMACODYNAMIC STUDIES
A 1 R (ant)agonists
PET has important applications in the study of pharmacodynamics, i.e. assessment of the effects of drugs in the healthy and diseased body, including their mechanisms of action and the relationship between drug concentration and effect. During the development of CNS drugs, PET is often used to measure the dose-dependent occupancy of target receptors in the human brain by a non-radioactive test compound. PET is also capable of measuring the metabolic response of tissues to treatment quantitatively, repeatedly and noninvasively, both in experimental animals and humans.
Only a few PET studies regarding A 1 R occupancy by cold antagonists have been reported in the literature. An interesting paper from Germany showed that the binding of 18 F-CPFPX in rat brain is reduced after treatment of animals with caffeine, shortly before injection of the tracer. At a dose of 4 mg/kg, corresponding to consumption of three to four cups of coffee by a human being, tracer binding was strongly (ca. 50%) suppressed, suggesting ~70% receptor occupancy [223] . Another study showed that 18 F-CPFPX bound to A 1 R in human brain can be dose-dependently displaced by injecting non-radioactive CPFPX [224] . A microPET study from our own group has indicated that A 1 R in rat brain are almost completely occupied after administration of DPCPX (3 mg/kg, i.p.), 20 min before injection of 11 C-MPDX [126] .
Thus, the dose-dependent occupancy of A 1 R in the brain by test drugs may be assessed by PET. Dose-dependent effects of A 1 R agonists (or AK inhibitors, see 4.2) on organ metabolism could be assessed as well, using the radiolabeled glucose analog [ 18 F]FDG, but such studies have not yet been reported.
AK Inhibitors
AK regulates intra-and extracellular adenosine concentrations by phosphorylation of adenosine to AMP. Although ADA also removes adenosine by converting it to inosine, the reaction catalyzed by AK is the most important pathway of adenosine removal under physiological conditions [225] . Since the major adenosine-specific nucleoside carrier acts as a non-concentrative, bi-directional, facilitated diffusion transporter, adenosine transport is driven by the concentration gradient across the cell membrane. Inhibition of AK raises intracellular adenosine, diminishes the concentration gradient and decreases the cellular uptake of adenosine, resulting in increased extracellular adenosine concentrations, particular under pathophysiological conditions and in tissues or brain regions where the formation of adenosine is increased by net catabolism of ATP [226] [227] [228] . An in vivo study in rats has shown that AK inhibitors (AKIs) augment the increases of extracellular adenosine during excitotoxic insults in the striatum but do not affect striatal adenosine levels in vehicle-treated controls [228] . Thus, AKIs represent a strategy for potentiating the protective actions of endogenous adenosine during tissue trauma [229] . This therapeutic approach may be advantageous in cases where not a single subtype (e.g., A 1 R) but rather a multiplicity of AR subtypes should be stimulated for the beneficial effect [230] .
Three applications of AKIs have been proposed. First, intrathecally administered AR agonists [231] [232] [233] and AKIs [232] [233] [234] have antinociceptive effects in experimental animals. These effects are counteracted by selective A 1 R antagonists but not by A 2A R antagonists suggesting involvement of A 1 R stimulation [228, 232, 235, 236] . Novel AKIs such as ABT-702 and A-286501 can also be given subcutaneously or orally and are then effective in animal models of acute, inflammatory and neuropathic pain [235, [237] [238] [239] . Substantial interest in the use of AKIs was raised by the fact that these compounds can be equally effective as morphine for the suppression of pain but show less potential to develop tolerance [238, 240, 241] . The use of AKIs rather than AR agonists allows an adequate separation between antinociceptive and motorimpairing effects [242] .
Second, AR agonists and AKIs have shown anti-inflammatory efficacy in various animal models of acute and chronic inflammation [238, 239, [243] [244] [245] [246] [247] [248] .
A third potential application of AKIs is in the treatment of epilepsy. These compounds suppress seizures in rodent models, such as the bicuculline-induced seizure [249] and the maximal electroshock [170, 250, 251] model, presumably via an interaction of adenosine with cerebral A 1 R. For that reason and because upregulation of the enzyme AK is involved in epileptogenesis [171] , AKIs are considered promising anticonvulsants [170, 252, 253] .
If a ligand could be developed of which the binding is sensitive to competition by endogenous adenosine, PET imaging could be applied to assess changes of extracellular adenosine induced by AKIs.
CONCLUSION
The purine nucleoside adenosine and its A 1 R are implied in many physiological functions, such as regulation of the sleep-wake cycle, aggression, and anxiety, habituation of animals to a novel environment, protection of cells against the negative consequences of hypoxia and ischemia. Adenosinergic signaling is also implied in ethanol-induced motor impairment, and withdrawal symptoms after ethanol abuse. Stimulation of A 1 R has anticonvulsant and antiinflammatory actions. Changes of A 1 R expression have been noted in animal models of epilepsy, the micro-environment of brain tumors, and various diseases of the human CNS such as AD, Pick's disease, Creutzfeld-Jakob disease, MS and schizophrenia. Since appropriate ligands for PET imaging of A 1 R are now available, PET can be applied to elucidate the role of A 1 R in the normal and diseased human brain and to study the pharmacodynamics of A 1 R agonists and AKI.
